Abstract
Multicentric Castleman disease (MCD) is a rare, systemic lymphoproliferative disorder driven by interleukin (IL)-6 overproduction. Siltuximab, an anti-IL-6 monoclonal antibody, has demonstrated durable tumor and symptomatic responses in a multinational, randomized, placebo-controlled study of MCD. This preplanned safety analysis was conducted to evaluate the long-term safety of siltuximab treatment among 19 patients with MCD who had stable disease or better and were enrolled in a phase-1 study and subsequent ongoing, open-label, phase-2 extension study. Dosing was 11 mg/kg administered intravenously every 3 weeks, per protocol, or every 6 weeks at the investigator's discretion. Safety monitoring focused on potential risks associated with the anti-IL-6 mechanism of action. Investigator-assessed disease control status was also documented. Median treatment duration for the 19 patients was 5.1 (range 3.4, 7.2) years, with 14 (74%) patients treated for >4 years. Grade-≥ 3 adverse events (AEs) reported in >1 patient included hypertension (n = 3) and nausea, cellulitis, and fatigue (n = 2 each). Grade-≥ 3 AEs at least possibly attributed to siltuximab were leukopenia, lymphopenia, and a serious AE of polycythemia (n = 1 each). Hypertr...Continue Reading
References
Apr 2, 2005·British Journal of Haematology·Corey Casper
Jul 7, 2005·Blood·Norihiro NishimotoTadamitsu Kishimoto
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frits van RheeRazelle Kurzrock
Jul 14, 2012·American Journal of Hematology·Angela DispenzieriThomas M Habermann
May 11, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Razelle KurzrockFrits van Rhee
Jun 12, 2013·Atherosclerosis·Aart C StrangPaul P Tak
Jul 22, 2014·The Lancet Oncology·Frits van RheeCorey Casper
Citations
Dec 3, 2015·Expert Review of Clinical Immunology·Emma Mitchell, Graeme Jones
Jun 25, 2014·Drugs·Anthony Markham, Trina Patel
Jan 20, 2017·Blood·Li YuKen H Young
Dec 3, 2016·Therapeutic Advances in Hematology·Shayna SarosiekNikhil C Munshi
Dec 5, 2015·Immunotherapy·David C Fajgenbaum, Razelle Kurzrock
Sep 6, 2018·Blood·Frits van RheeDavid C Fajgenbaum
Dec 7, 2018·Hematology·David C Fajgenbaum
Aug 28, 2020·The Oncologist·Li YuKen H Young
Sep 24, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Katherine A Lyseng-Williamson
Feb 1, 2017·Expert Opinion on Investigational Drugs·Andrea FerrarioFrancesco Passamonti
Jan 10, 2018·Nature Reviews. Clinical Oncology·Irene M GhobrialDavid P Steensma
Nov 30, 2018·Blood·David C Fajgenbaum
Jul 29, 2019·AIDS Research and Therapy·Laura CampogianiLoredana Sarmati
Sep 8, 2020·American Journal of Hematology·David C FajgenbaumUNKNOWN Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatm
Feb 13, 2018·Oncology Letters·Jin-Peng JiangWen-Xian Guan
Jun 20, 2020·Drugs in R&D·Paul C MacklisBenjamin H Kaffenberger
Aug 9, 2020·Curēus·Philip R CohenRazelle Kurzrock
Apr 27, 2017·Mycoses·Ioannis KyriakidisAndreas H Groll
Aug 4, 2018·Hematological Oncology·Lorenzo TonialiniPier Luigi Zinzani
Apr 17, 2019·Pediatric Blood & Cancer·Ang WeiTianyou Wang
Apr 27, 2020·Infectious Disease Clinics of North America·Anne Y Liu
Aug 26, 2021·European Journal of Haematology·Aaron M GoodmanRazelle Kurzrock
Sep 19, 2021·The FEBS Journal·Kwun Wah WenBlossom Damania